Athira Pharma, Inc. (NASDAQ:LONA) Given Average Recommendation of “Hold” by Brokerages

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been given a consensus recommendation of “Hold” by the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $15.00.

A number of brokerages recently issued reports on LONA. Cantor Fitzgerald began coverage on Athira Pharma in a report on Thursday, February 26th. They set an “overweight” rating on the stock. Piper Sandler began coverage on Athira Pharma in a report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Athira Pharma in a report on Monday, May 11th. Zacks Research upgraded Athira Pharma to a “hold” rating in a report on Friday, February 27th. Finally, Wall Street Zen upgraded Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

Athira Pharma Stock Performance

Shares of NASDAQ:LONA opened at $8.69 on Friday. Athira Pharma has a 1 year low of $2.85 and a 1 year high of $14.21. The stock has a market cap of $81.60 million, a P/E ratio of -1.67 and a beta of 1.97. The firm’s 50-day simple moving average is $9.16.

Athira Pharma (NASDAQ:LONA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.73) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Athira Pharma will post -3.12 earnings per share for the current fiscal year.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.